Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non-alcoholic fatty liver disease and psoriasis: So far, so near
Giulia Ganzetti, Anna Campanati, Annamaria Offidani
World Journal of Hepatology (2015) Vol. 7, Iss. 3, pp. 315-315
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies
José María García Ruiz de Morales, L. Puig, E. Daudén, et al.
Autoimmunity Reviews (2019) Vol. 19, Iss. 1, pp. 102429-102429
Open Access | Times Cited: 275
Nonalcoholic fatty liver disease - A multisystem disease?
Ivana Mikolašević, Sandra Milić, Tamara Turk Wensveen, et al.
World Journal of Gastroenterology (2016) Vol. 22, Iss. 43, pp. 9488-9488
Open Access | Times Cited: 177
NAFLD and Extra-Hepatic Comorbidities: Current Evidence on a Multi-Organ Metabolic Syndrome
Valerio Rosato, Mario Masarone, Marcello Dallio, et al.
International Journal of Environmental Research and Public Health (2019) Vol. 16, Iss. 18, pp. 3415-3415
Open Access | Times Cited: 117
Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
Lisa B. VanWagner, Mary E. Rinella
Current Hepatology Reports (2016) Vol. 15, Iss. 2, pp. 75-85
Open Access | Times Cited: 100
Incidence and Predictors of Nonalcoholic Fatty Liver Disease by Serum Biomarkers in Patients with Inflammatory Bowel Disease
Talat Bessissow, Ngoc Han Le, Kathleen Rollet, et al.
Inflammatory Bowel Diseases (2016) Vol. 22, Iss. 8, pp. 1937-1944
Open Access | Times Cited: 97
Extrahepatic Manifestations of Nonalcoholic Fatty Liver Disease
Andrew A. Li, Aijaz Ahmed, Donghee Kim
Gut and Liver (2019) Vol. 14, Iss. 2, pp. 168-178
Open Access | Times Cited: 93
The bidirectional immune crosstalk in metabolic dysfunction-associated steatotic liver disease
Keisuke Sawada, Hak‐Jae Chung, Samir Softic, et al.
Cell Metabolism (2023) Vol. 35, Iss. 11, pp. 1852-1871
Open Access | Times Cited: 36
Role of MicroRNAs in NAFLD/NASH
Gyöngyi Szabó, Tímea Csák
Digestive Diseases and Sciences (2016) Vol. 61, Iss. 5, pp. 1314-1324
Closed Access | Times Cited: 82
Co-existence of non-alcoholic fatty liver disease and inflammatory bowel disease: A review article
Che‐Yung Chao, Robert Battat, Alex Al Khoury, et al.
World Journal of Gastroenterology (2016) Vol. 22, Iss. 34, pp. 7727-7727
Open Access | Times Cited: 81
Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?
Ronald Prussick, Luca Miele
British Journal of Dermatology (2017) Vol. 179, Iss. 1, pp. 16-29
Open Access | Times Cited: 73
Gut inflammation exacerbates hepatic injury in the high-fat diet induced NAFLD mouse: Attention to the gut-vascular barrier dysfunction
Chunwei Cheng, Jun Tan, Wei Qian, et al.
Life Sciences (2018) Vol. 209, pp. 157-166
Closed Access | Times Cited: 72
Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background
Giulia Ganzetti, Anna Campanati, Elisa Molinelli, et al.
World Journal of Cardiology (2016) Vol. 8, Iss. 2, pp. 120-120
Open Access | Times Cited: 46
Extra-Hepatic Manifestations and Complications of Nonalcoholic Fatty Liver Disease
Stefano Ballestri, Alessandro Mantovani, Fabio Nascimbeni, et al.
Future Medicinal Chemistry (2019) Vol. 11, Iss. 16, pp. 2171-2192
Closed Access | Times Cited: 37
Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies
Deepak Balak, Stefano Piaserico, Ismail Kasujee
Psoriasis Targets and Therapy (2021) Vol. Volume 11, pp. 151-168
Open Access | Times Cited: 30
Effect of low-calorie diet on psoriasis severity index, triglycerides, liver enzymes, and quality of life in psoriatic patients with non-alcoholic fatty liver disease
Ali Mohamed Ali Ismail, Ahmad Saad, Ramy Salama Draz
Reumatologia/Rheumatology (2023) Vol. 61, Iss. 2, pp. 116-122
Open Access | Times Cited: 12
Biologic therapy for psoriasis is associated with the development of metabolic dysfunction-associated steatotic liver disease (MASLD). A study on the association of cardiometabolic conditions with psoriasis treatment
Gwyneth Armijo-Borjon, Alessandra Irais Miranda-Aguirre, Arnulfo Garza-Silva, et al.
Archives of Dermatological Research (2025) Vol. 317, Iss. 1
Closed Access
Psoriatic inflammation causes hepatic inflammation with concomitant dysregulation in hepatic metabolism via IL-17A/IL-17 receptor signaling in a murine model
Naif O. Al‐Harbi, Ahmed Nadeem, Mohammed M. Al‐Harbi, et al.
Immunobiology (2016) Vol. 222, Iss. 2, pp. 128-136
Closed Access | Times Cited: 37
Psoriasis e hígado graso no alcohólico
J.M. Carrascosa, Clara Bonanad, E. Daudén, et al.
Actas Dermo-Sifiliográficas (2017) Vol. 108, Iss. 6, pp. 506-514
Closed Access | Times Cited: 37
Safety and effectiveness of guselkumab in Japanese patients with psoriasis: 20‐week interim analysis of a postmarketing surveillance study
Yayoi Tada, Yukako Sugiura, Manami Kamishima, et al.
The Journal of Dermatology (2024) Vol. 51, Iss. 6, pp. 779-790
Open Access | Times Cited: 3
Myeloid-derived suppressor cells are elevated in patients with psoriasis and produce various molecules
Dan Ilkovitch, Laura K. Ferris
Molecular Medicine Reports (2016) Vol. 14, Iss. 4, pp. 3935-3940
Open Access | Times Cited: 28
Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis
Anna Campanati, Matteo Paolinelli, Federico Diotallevi, et al.
Expert Opinion on Drug Metabolism & Toxicology (2019) Vol. 15, Iss. 11, pp. 913-925
Closed Access | Times Cited: 28
Comorbid Psoriasis and Metabolic Syndrome: Clinical Implications and Optimal Management
Eveline De Brandt, Tom Hillary
Psoriasis Targets and Therapy (2022) Vol. Volume 12, pp. 113-126
Open Access | Times Cited: 14
Psoriasis and Nonalcoholic Fatty Liver Disease
J.M. Carrascosa, Clara Bonanad, E. Daudén, et al.
Actas Dermo-Sifiliográficas (2017) Vol. 108, Iss. 6, pp. 506-514
Open Access | Times Cited: 27
Certolizumab pegol for the treatment of psoriasis
Anna Campanati, Devis Benfaremo, Michele Maria Luchetti, et al.
Expert Opinion on Biological Therapy (2017) Vol. 17, Iss. 3, pp. 387-394
Closed Access | Times Cited: 25
Diagnostic performance of transient elastography for detection of methotrexate-induced liver injury using Roenigk classification in Asian patients with psoriasis: a retrospective study
Pasinee Rongngern, Leena Chularojanamontri, Chanisada Wongpraparut, et al.
Archives of Dermatological Research (2017) Vol. 309, Iss. 5, pp. 403-408
Closed Access | Times Cited: 24
Page 1 - Next Page

Scroll to top